Review compares efficacy and safety of gene therapies Casgevy and Lyfgenia with hematopoietic stem cell transplantation, indicating new treatment options for sickle cell disease.
Key Points
Hemoglobin disorders like sickle cell disease affect about 2.1% of Bahrain's population, necessitating effective treatment options.
Hematopoietic stem cell transplantation has a 90% success rate but faces challenges like donor availability and toxicity.
Gene therapies Casgevy and Lyfgenia show promise in reducing complications of sickle cell disease while avoiding HSCT limitations.
Bahrain's approval of Casgevy in December 2023 represents a significant step toward advanced treatment options for sickle cell disease.